查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950489

膝下动脉支架市场（按产品、手术、适应症、植入位置、最终用户和分销管道划分），全球预测，2026-2032年

Infrapopliteal Artery Stent Market by Product, Procedure, Indication, Implant Location, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，腿部动脉支架市场价值将达到 20.2 亿美元，到 2026 年将成长至 22 亿美元，到 2032 年将达到 41.5 亿美元，年复合成长率为 10.83%。

关键市场统计数据
基准年 2025 20.2亿美元
预计年份：2026年 22亿美元
预测年份 2032 41.5亿美元
复合年增长率 (%) 10.83%

下膝动脉支架环境简明框架：重点关注临床需求、供应考虑和不断变化的医疗机构采用趋势

小腿动脉支架在现代下肢周边动脉疾病的治疗中发挥核心作用，特别适用于涉及胫动脉和腓动脉床的病变。近年来，支架设计和药物传递技术的临床进展重塑了手术决策，使介入团队能够应对复杂的解剖结构，并在保肢的同时降低血管再阻塞的风险。因此，临床医生和医疗系统越来越倾向于从病变特征、患者合併症以及预期长期通畅率等综合观点来评估器械的选择。

材料创新、药物释放型技术的进步以及手术流程的改变如何重塑下肢血管介入治疗中的器械选择和临床路径

膝下动脉支架植入术领域正经历变革性的转变，材料科学的创新、先进的药物释放型技术以及不断改进的手术流程正在重塑临床决策。生物可吸收支架设计和聚合物工程的最新进展，有助于在维持短期血管完整性的同时，减少慢性异物反应，促使介入医师采用更精细的选择标准。同时，覆膜支架结构和密封技术的进步，正在改善复杂病变亚组的治疗效果，并促使人们在病变形态或血流（流向外周血管的血流）需要特殊解决方案时，考虑针对特定器械的适应症。

评估2025年美国关税对采购、价格谈判和供应韧性的营运和策略影响

2025年美国关税调整对膝下支架供应链中的製造商、经销商和医疗器材采购商产生了复杂的营运和战略影响。某些进口医疗设备组件关税的提高，给依赖跨境采购特种合金、聚合物和药物释放型化合物的製造商带来了到岸成本上行压力。为此，供应链管理人员立即重新评估了供应商组合，尽可能优先考虑区域采购，并加快供应商资格认证流程，以确保在关税波动期间生产的连续性。

将下肢动脉领域的器械选择和商业化策略与按产品类型、临床环境和手术阶段分類的详细細項分析联繫起来

一个完善的细分框架阐明了产品类型、最终用户、分销管道、手术分类、临床适应症和植入部位如何各自对临床应用和商业策略产生不同的影响。产品细分比较了裸金属支架、生物可吸收支架、覆膜支架和药物释放型支架，并指出药物释放型技术进一步细分为生物可吸收和永久性聚合物两种类型，每种类型对发炎反应、药物递送动力学和临床医生偏好的影响各不相同。最终用户细分突显了门诊手术中心、医院和专科诊所在采购趋势和临床工作流程方面的差异，这些机构的病例组合、医疗设备库存政策和库存管理实践都存在显着差异。

美洲、欧洲、中东和非洲以及亚太地区的区域性因素将决定监管应对措施、推广速度和商业化策略。

区域趋势对监管路径、报销机制和临床偏好产生了重大影响，进而影响着膝下支架技术在不同医疗体系中的引入和推广。在美洲，临床医师对血管内手术的熟悉程度以及医院成熟的采购机制，往往有利于快速采用渐进式器械创新。然而，支付方和医疗体系越来越需要与临床结果和总医疗成本相关的可靠价值证明。因此，希望在该地区实现商业化的製造商高度重视真实世界数据（RWE）的生成、上市后监测以及与主要医疗体系达成按绩效付费协议。

创新通路、实证项目和市场推广模式塑造了支架器材公司的竞争差异化和长期商业性永续性。

膝下支架领域的竞争日益激烈，其驱动因素包括差异化的技术组合、已证实的临床证据以及为临床医生和医疗系统提供整合服务的能力。大型器械开发商投资于下一代药物释放型化学、聚合物科学和低轮廓输送系统，使其能够应对复杂的胫腓骨解剖结构；而规模较小的创新者则专注于涂层治疗和生物可吸收支架等细分应用，以满足特定的血管再阻塞和闭合需求。除了器械性能外，能够透过结构化的临床计画和註册研究证明可重复的手术结果的公司，更有可能赢得临床医生的信任和医疗机构的广泛采用。

以行动为导向的策略重点，将临床证据产生、供应链韧性和区域商业化连结起来，以加速永续的医疗器材普及应用。

为了在膝下护理领域实现持续价值，产业领导者应优先考虑协作策略，将产品创新与临床医生的需求、营运实际情况和支付方的期望相结合。这首先需要投资于有针对性的临床项目，以产生与手术特异性的证据，从而将器械属性与有意义的患者预后联繫起来。应着重于註册研究和务实的试验设计，并辅以随机对照试验数据。这些证据必须转化为清晰的价值提案，供医院采购团队和门诊服务提供者参考，重点在于阐述器械选择如何影响手术效率、再次手术率和病患復健路径。

严谨的多源调查方法，结合临床文献综述、监管分析以及与关键相关人员的面对面访谈，确保了研究结果的平衡性和可操作性。

本研究采用多方面方法，整合了同行评审的临床文献、监管文件、医疗设备附加檔以及对临床医生、供应链专家和商业领袖的访谈，以全面了解技术、临床和市场动态。研究评估了临床证据，包括研究设计品质、患者族群特征、病变特异性结局和追踪期，以确定研究结果对常见腘窝下适应症的适用性。此外，研究还审查了监管路径和核准情况，以了解市场进入要求并识别不同司法管辖区上市后警戒期望的差异。

整合设备创新、临床应用因素和营运要求，为下肢动脉疾病治疗的进展制定切实可行的方案

总而言之，膝下支架领域呈现出多种因素交会融合的特征：器械创新、手术流程演进和商业性整合，这些因素共同塑造着临床医生和医疗系统进行下肢重组的方式。药物释放型化学、聚合物技术和支架设计的进步拓展了治疗选择，但不断变化的医疗环境和日益增长的采购压力要求製造商提供清晰的临床益处、物流可行性和经济价值的证据。 2025年关税带来的衝击进一步凸显了供应链弹性和透明成本模型对于维持治疗可近性和可负担性的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 膝下动脉支架市场（依产品划分）

  • 裸金属支架
  • 生物可吸收支架
  • 覆膜支架
  • 药物释放型支架
    • 生物可吸收聚合物
    • 永久聚合物

9. 依手术方式分類的膝下动脉支架市场

  • 首次植入
  • 血管再阻塞管理
    • 新病变
    • 支架内血管再阻塞

第十章 依适应症分類的膝下动脉支架市场

  • 严重肢体缺血
  • 间歇性跛行

第十一章 依植入部位分類的膝下动脉支架市场

  • 胫前动脉
  • 腓动脉
  • 胫后动脉

第十二章 膝下动脉支架市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章 膝下动脉支架市场（依通路划分）

  • 直接竞标
  • 经销商
  • 线上管道

第十四章 膝下动脉支架市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 膝下动脉支架市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国膝下动脉支架市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国膝下支架市场

第十八章：中国膝下动脉支架市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CR Bard, Inc.
  • Cardiovascular Systems, Inc.
  • Cook Medical, Inc.
  • Cordis LLC
  • Endologix, Inc.
  • Gore Medical
  • iVascular SLU
  • Jotec GmbH
  • Lombard Medical Technologies
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Synectic Medical Limited
  • Teleflex Incorporated
  • Terumo Corporation
  • Translumina GmbH
  • WL Gore & Associates, Inc.
Product Code: MRR-4F7A6D4FD898

The Infrapopliteal Artery Stent Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.20 billion in 2026, with a CAGR of 10.83%, reaching USD 4.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.20 billion
Forecast Year [2032] USD 4.15 billion
CAGR (%) 10.83%

Concise framing of the infrapopliteal stent environment highlighting clinical imperatives, supply considerations, and evolving provider adoption dynamics

Infrapopliteal artery stents are central to contemporary management of peripheral arterial disease affecting the lower extremities, particularly when lesions involve the tibial and peroneal vascular beds. Recent clinical advances in stent design and drug delivery have reshaped procedural decision making, enabling interventional teams to address complex anatomies and mitigate restenosis risk while balancing limb salvage objectives. As a result, clinicians and health systems increasingly evaluate device selection through a lens that integrates lesion characteristics, patient comorbidity profiles, and expected long-term patency outcomes.

Beyond clinical performance, the landscape is influenced by supply chain resilience, vendor service models, and the evolving reimbursement environment which together affect hospital purchasing pathways and ambulatory care adoption. Transitional shifts in outpatient procedural settings and the growing emphasis on clinician-led value demonstrations require manufacturers to align evidence generation with real-world utilization patterns. Consequently, stakeholders must synthesize clinical evidence, operational feasibility, and regulatory constraints to craft strategies that support both improved patient outcomes and sustainable commercial performance.

This introduction frames the subsequent analysis by clarifying the key levers-technology innovation, clinical pathways, and commercial dynamics-that are driving choices at institutional and provider levels when treating infrapopliteal disease.

How material innovation, drug-elution advances, and procedural shifts are reshaping device selection and clinical pathways for lower limb vascular interventions

The infrapopliteal stent arena is experiencing transformative shifts driven by material science innovations, refined drug-elution technologies, and procedural workflow evolution that collectively reconfigure clinical decision making. Recent developments in bioresorbable scaffold design and polymer engineering have opened pathways to reduce chronic foreign-body responses while maintaining short-term vessel scaffolding, and consequently have prompted more nuanced selection criteria among interventionalists. At the same time, advances in covered stent construction and the refinement of sealing technologies have improved outcomes in complex lesion subsets, encouraging consideration of device-specific applications where lesion morphology and runoff demand targeted solutions.

Parallel to device innovation, procedural shifts toward ambulatory and hybrid care models are influencing how providers prioritize device profiles that enable rapid recovery and low complication rates. These delivery-model changes reinforce the need for manufacturers to demonstrate not only clinical efficacy but also economic and logistical compatibility with outpatient workflows. Moreover, the acceleration of digital health tools and imaging integration facilitates more precise lesion assessment and tailored stent deployment, thereby enhancing procedural predictability. Taken together, these trends are redefining value propositions and prompting stakeholders to re-evaluate clinical pathways, evidence strategies, and commercialization approaches to remain competitive.

Assessing the operational and strategic reverberations of the United States tariff measures in 2025 that influenced sourcing, pricing negotiations, and supply resilience

Tariff adjustments implemented in 2025 by the United States introduced a complex layer of operational and strategic implications for manufacturers, distributors, and healthcare purchasers involved in infrapopliteal stent supply chains. Increased duties on certain imported medical device components created upward pressure on landed costs for manufacturers reliant on cross-border sourcing of specialized alloys, polymers, and drug-eluting compounds. As an immediate response, supply-chain managers reassessed vendor portfolios, prioritized regional sourcing where feasible, and accelerated supplier qualification processes to insulate production continuity from tariff volatility.

In addition, the tariffs prompted pricing discussions between vendors and institutional purchasers, with contract renegotiations increasingly referencing total landed cost and service-level guarantees. For some manufacturers, the tariffs stimulated investments in localized manufacturing capacity to reduce exposure to import duties and to expedite time-to-market for iterative device improvements. From a downstream perspective, hospitals and ambulatory centers engaged more actively with procurement partners to understand the net impact on contract value and device availability, paying particular attention to the interplay between device cost, reimbursement pathways, and clinical outcomes. Overall, the cumulative effect of the 2025 tariffs reinforced the importance of flexible sourcing, transparent cost modeling, and collaborative commercial agreements to preserve access and manage cost pressures across the care continuum.

Granular segmentation insights linking product types, care settings, and procedural distinctions to device selection and commercialization strategies across infrapopliteal applications

A robust segmentation framework clarifies how product types, end users, distribution channels, procedural classifications, clinical indications, and implant locations each exert distinct influences on clinical adoption and commercial strategy. Product segmentation contrasts bare metal stents, bioresorbable scaffolds, covered stents, and drug-eluting stents, and recognizes that drug-eluting technologies further bifurcate into bioabsorbable polymer and permanent polymer approaches, each with distinct implications for inflammatory response, drug delivery kinetics, and clinician preference. End-user segmentation highlights differences in procurement dynamics and clinical workflows across ambulatory surgical centers, hospitals, and specialty clinics, where case mix, device stocking policies, and inventory management practices vary substantially.

Distribution channel distinctions between direct tender, distributor networks, and online channels affect turnaround times, contractual complexity, and service provision, while procedure-based segmentation between primary implantation and restenosis management-where restenosis management itself separates into de novo lesion treatment and in-stent restenosis modalities-shapes device selection criteria tied to lesion history and vessel biology. Indication-driven segmentation separating critical limb ischemia from intermittent claudication underscores divergent clinical priorities, with limb salvage imperatives often elevating the importance of long-term patency and reintervention risks. Finally, implant-location segmentation across anterior tibial, peroneal, and posterior tibial arteries draws attention to device profile, flexibility, and deliverability requirements driven by vessel calibre and tortuosity. Collectively, this layered segmentation supports systematic alignment of product development, evidence generation, and go-to-market tactics that map to distinct clinical and purchasing realities.

Regional considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory navigation, adoption pacing, and commercialization approaches

Regional dynamics materially influence regulatory pathways, reimbursement practices, and clinical preferences, shaping how infrapopliteal stent technologies are introduced and scaled across different healthcare systems. In the Americas, clinician familiarity with endovascular approaches and established hospital procurement mechanisms often facilitate rapid adoption of incremental device innovations, yet payers and health systems increasingly require robust value demonstration tied to clinical outcomes and total cost of care. Consequently, manufacturers pursuing commercialization in this region emphasize real-world evidence generation, post-market surveillance, and collaborative outcome-based agreements with major health systems.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse reimbursement landscapes create both opportunities and complexities for device manufacturers. European centers of excellence tend to adopt evidence-driven innovations where clinical guidance and multicenter data support practice change, while in the Middle East and Africa device access and adoption hinge on local procurement policies and programmatic investments in vascular services. By contrast, Asia-Pacific presents a heterogeneous set of adoption pathways influenced by strong domestic manufacturing capabilities in several markets, differing regulatory timelines, and a growing emphasis on cost-effectiveness in public procurement. Transitioning between regions, manufacturers must adapt regulatory strategies, clinical engagement models, and distribution frameworks to reflect local payer expectations, procedural norms, and infrastructure capabilities.

How innovation pipelines, evidence programs, and go-to-market models shape competitive differentiation and long-term commercial resilience in stent device companies

Competitive intensity in the infrapopliteal stent sector is driven by differentiated technology portfolios, evidence credentials, and the ability to deliver integrated services that support clinicians and health systems. Leading device developers that invest in next-generation drug-elution chemistry, polymer science, and low-profile delivery systems position themselves to address complex tibial and peroneal anatomies, while smaller innovators focus on niche applications such as covered therapies or bioresorbable scaffolds that address specific restenosis or sealing requirements. Beyond device performance, companies that can demonstrate reproducible procedural outcomes through structured clinical programs and registries tend to achieve stronger clinician trust and institutional adoption.

Moreover, channel strategies and commercial support models-ranging from direct tender engagement with large hospital systems to distributor-managed inventories and expanding online procurement platforms-shape competitive advantage. Firms that integrate training programs, procedural simulation, and localized clinical support reduce adoption friction and create durable clinical partnerships. Finally, strategic collaborations between device developers, contract manufacturers, and logistics providers help mitigate supply-chain risks and support scalable deployments across varied care settings. These competitive dynamics encourage continuous investment in clinical evidence, operational excellence, and differentiated service offerings to sustain long-term relevance in the marketplace.

Action-oriented strategic priorities that align clinical evidence generation, supply resilience, and localized commercialization to accelerate sustainable device adoption

Industry leaders should prioritize a coordinated strategy that aligns product innovation with clinician needs, operational realities, and payer expectations to capture durable value in infrapopliteal interventions. First, invest in targeted clinical programs that generate procedure-specific evidence linking device features to meaningful patient outcomes, with a focus on registries and pragmatic trial designs that complement randomized data. This evidence must then be translated into clear value narratives for hospital procurement teams and ambulatory care providers, emphasizing how device selection affects procedural efficiency, reintervention rates, and patient recovery pathways.

Second, optimize supply-chain flexibility by diversifying component sourcing and evaluating regional manufacturing options to reduce exposure to policy-driven cost fluctuations. Third, tailor commercialization approaches to local care delivery models by deploying differentiated sales and service footprints that support training, inventory management, and outcome monitoring. Fourth, cultivate strategic partnerships with imaging providers, digital health vendors, and reimbursement advisors to create integrated solutions that simplify adoption for clinicians and purchasing stakeholders. Lastly, maintain a disciplined approach to post-market surveillance and iterative product improvement, ensuring that clinical feedback loops inform next-generation design and service enhancements. These coordinated actions will enable organizations to navigate complexity while sustaining clinical credibility and commercial momentum.

Rigorous multi-source methodology combining clinical literature review, regulatory analysis, and primary stakeholder interviews to ensure balanced and actionable insights

This research adopted a multi-method approach combining synthesis of peer-reviewed clinical literature, regulatory documentation, device labeling, and primary interviews with clinicians, supply-chain professionals, and commercial leaders to construct a balanced view of technological, clinical, and market dynamics. Clinical evidence was evaluated for study design quality, patient population characteristics, lesion-specific outcomes, and follow-up duration to determine the applicability of results across common infrapopliteal indications. Regulatory pathways and approvals were reviewed to map market access requirements and to identify emergent differences in post-market surveillance expectations across jurisdictions.

Primary qualitative interviews provided context on procurement practices, clinician device preferences, and procedural workflow constraints, while secondary analysis of public filings and clinical registries helped corroborate adoption drivers and product positioning. Care was taken to triangulate findings across multiple independent sources to mitigate single-source bias, and methodological limitations-such as variation in lesion definitions and heterogeneity in follow-up protocols-were explicitly considered when interpreting comparative device performance. Together, these methods yield a pragmatic, evidence-informed perspective intended to support operational decision making and strategic planning.

Synthesis of device innovation, clinical adoption factors, and operational imperatives that define practical pathways for advancing infrapopliteal patient care

In summary, the infrapopliteal stent landscape is characterized by converging forces of device innovation, procedural evolution, and commercial realignment that together shape how clinicians and health systems approach lower limb revascularization. Advances in drug-elution chemistries, polymer technologies, and scaffold design have expanded therapeutic options, while changing care settings and procurement pressures necessitate that manufacturers provide clear evidence of clinical benefit, logistical compatibility, and economic value. The 2025 tariff-driven disruptions further underscored the need for supply-chain agility and transparent cost modeling to sustain access and affordability.

Looking forward, successful organizations will be those that translate technical differentiation into reproducible clinical outcomes, demonstrate operational alignment with diverse care settings, and engage proactively with payers and providers to articulate compelling value propositions. By integrating targeted evidence generation, resilient sourcing strategies, and localized commercialization plans, stakeholders can better navigate the evolving environment and support improved patient outcomes in peripheral arterial disease management. This conclusion reinforces the practical imperatives for device developers, clinical leaders, and procurement teams as they plan next steps.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infrapopliteal Artery Stent Market, by Product

  • 8.1. Bare Metal Stent
  • 8.2. Bioresorbable Scaffold
  • 8.3. Covered Stent
  • 8.4. Drug Eluting Stent
    • 8.4.1. Bioabsorbable Polymer
    • 8.4.2. Permanent Polymer

9. Infrapopliteal Artery Stent Market, by Procedure

  • 9.1. Primary Implantation
  • 9.2. Restenosis Management
    • 9.2.1. De Novo Lesion
    • 9.2.2. In-Stent Restenosis

10. Infrapopliteal Artery Stent Market, by Indication

  • 10.1. Critical Limb Ischemia
  • 10.2. Intermittent Claudication

11. Infrapopliteal Artery Stent Market, by Implant Location

  • 11.1. Anterior Tibial Artery
  • 11.2. Peroneal Artery
  • 11.3. Posterior Tibial Artery

12. Infrapopliteal Artery Stent Market, by End User

  • 12.1. Ambulatory Surgical Center
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Infrapopliteal Artery Stent Market, by Distribution Channel

  • 13.1. Direct Tender
  • 13.2. Distributor
  • 13.3. Online Channel

14. Infrapopliteal Artery Stent Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Infrapopliteal Artery Stent Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Infrapopliteal Artery Stent Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Infrapopliteal Artery Stent Market

18. China Infrapopliteal Artery Stent Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. B. Braun Melsungen AG
  • 19.7. Becton, Dickinson and Company
  • 19.8. Biotronik SE & Co. KG
  • 19.9. Boston Scientific Corporation
  • 19.10. C.R. Bard, Inc.
  • 19.11. Cardiovascular Systems, Inc.
  • 19.12. Cook Medical, Inc.
  • 19.13. Cordis LLC
  • 19.14. Endologix, Inc.
  • 19.15. Gore Medical
  • 19.16. iVascular S.L.U.
  • 19.17. Jotec GmbH
  • 19.18. Lombard Medical Technologies
  • 19.19. Medtronic plc
  • 19.20. Meril Life Sciences Pvt. Ltd.
  • 19.21. MicroPort Scientific Corporation
  • 19.22. Synectic Medical Limited
  • 19.23. Teleflex Incorporated
  • 19.24. Terumo Corporation
  • 19.25. Translumina GmbH
  • 19.26. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COVERED STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COVERED STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COVERED STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY BIOABSORBABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERMANENT POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERMANENT POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERMANENT POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRIMARY IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRIMARY IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRIMARY IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ANTERIOR TIBIAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ANTERIOR TIBIAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ANTERIOR TIBIAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERONEAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERONEAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PERONEAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY POSTERIOR TIBIAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY POSTERIOR TIBIAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY POSTERIOR TIBIAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 158. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 159. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 186. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 195. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 197. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. NATO INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DRUG ELUTING STENT, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY RESTENOSIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY IMPLANT LOCATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA INFRAPOPLITEAL ARTERY STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)